Pfizer will invest $350mn in eastern China on a plant for biotechnology drugs, bolstering its presence in the world’s second-largest pharmaceutical market despite slowing economic growth in the country and rising pressure on prices for medicines.
The new facility in eastern Hangzhou city is expected to be completed in 2018 and will manufacture biologics, or complex medicines made from living organisms, as well as biosimilars for patients in China and across the world, Pfizer said in an e- mailed statement on Thursday.
Biosimilars are highly similar versions of biologic drugs that usually go through a complex manufacturing process. Making them requires greater precision than generics that copy relatively more straightforward chemical-based treatments.
The products from the plant will address major public health concerns such as oncology, the New York-based drugmaker said, without naming specific drugs. Biologics are underutilised in China, accounting for 4% of medicines prescribed in the country, compared with 22% in the US, according to the company.
A government-led campaign to reduce prices damped sales in China’s pharmaceutical industry and the nation’s economy has also slowed, leading to weaker sales growth in the country for drugmakers from Pfizer to the UK’s GlaxoSmithKline and AstraZeneca last year. Still, multinationals including Novartis continue to invest in China, where a rising middle class is boosting spending on health care.
“China is one of the fastest growing pharmaceutical markets in the world and the ongoing China healthcare reform will continue to drive the expansion of China’s pharmaceutical industry, including research and development,” Pfizer said in a separate e-mail.
The new Pfizer facility will be its first biotechnology centre in Asia and third globally, the company said. Novartis unveiled a $1bn campus in Shanghai this month, after Merck & Co opened a new research and development centre on the outskirts of Beijing in April.
A slow approval process in China has delayed the entry of some cutting-edge new medicines by foreign drugmakers. The Chinese regulator recently began taking steps to ease the problem, pledging to fast-track some much-needed therapies such as new drugs for hepatitis C, although it hasn’t given any firm timelines.
“We are glad to see that the Chinese authorities have recently issued a series of new policies to address this so called ‘drug lag,’ such as encouraging international multi-centred clinical trial application and supporting simultaneous native and international clinical trials,” Pfizer said.